Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Charles River Laboratories International Inc Stock Research

CRL

198.15USD-10.48(-5.02%)Market Closed
Watchlist

Market Summary

USD198.15-10.48
Market Closed
-5.02%

CRL Alerts

CRL Stock Price

CRL RSI Chart

CRL Valuation

Market Cap

10.2B

Price/Earnings (Trailing)

20.99

Price/Sales (Trailing)

2.43

EV/EBITDA

12.68

Price/Free Cashflow

16.25

CRL Price/Sales (Trailing)

CRL Profitability

EBT Margin

15.23%

Return on Equity

15.97%

Return on Assets

6.45%

Free Cashflow Yield

6.15%

CRL Fundamentals

CRL Revenue

Revenue (TTM)

4.2B

Revenue Y/Y

8.92%

Revenue Q/Q

2.97%

CRL Earnings

Earnings (TTM)

484.0M

Earnings Y/Y

-11.25%

Earnings Q/Q

-5.93%

Price Action

52 Week Range

181.22262.00
(Low)(High)

Last 7 days

2.5%

Last 30 days

3.8%

Last 90 days

2.2%

Trailing 12 Months

7.4%

CRL Financial Health

Current Ratio

1.48

Debt/Equity

0.88

Debt/Cashflow

0.23

CRL Investor Care

Shares Dilution (1Y)

0.87%

Diluted EPS (TTM)

9.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CRL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-24
WALLMAN RICHARD F
bought
198,786
198
1,000
-
2023-08-10
Knell Michael Gunnar
sold
-318,530
216
-1,471
csvp&chief accounting officer
2023-08-10
FOSTER JAMES C
gifted
-
-
-2,500
chairman, president and ceo
2023-08-10
LaPlume Joseph W
sold
-151,564
216
-700
evp, corp strategy & develop
2023-08-10
Barbo William D
sold
-1,251,950
217
-5,763
corporate executive vp & cco
2023-08-10
Knell Michael Gunnar
acquired
212,810
144
1,471
csvp&chief accounting officer
2023-08-10
Barbo William D
acquired
797,276
144
5,511
corporate executive vp & cco
2023-07-03
MACKAY MARTIN
acquired
-
-
95.00
-
2023-06-01
Knell Michael Gunnar
acquired
-
-
1,528
csvp&chief accounting officer
2023-05-31
MACKAY MARTIN
acquired
-
-
338
-

1–10 of 50

Which funds bought or sold CRL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
added
5.66
1,078
11,774
-%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
unchanged
-
24,598
613,509
0.07%
2023-09-05
Covenant Partners, LLC
unchanged
-
22,356
557,583
0.20%
2023-09-01
Portside Wealth Group, LLC
new
-
270,599
270,599
0.05%
2023-08-29
EFG Asset Management (Americas) Corp.
new
-
229,593
229,593
0.05%
2023-08-23
Stonebridge Capital Advisors LLC
added
766
4,862
5,467
-%
2023-08-22
COMERICA BANK
new
-
24,000
24,000
-%
2023-08-22
Asset Dedication, LLC
unchanged
-
1,000
19,000
-%
2023-08-21
BOKF, NA
added
0.9
61,875
1,271,380
0.03%
2023-08-21
VitalStone Financial, LLC
new
-
1,000
1,000
-%

1–10 of 48

Latest Funds Activity

Are funds buying CRL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRL
No. of Funds

Schedule 13G FIlings of Charles River Laboratories International

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 07, 2023
blackrock inc.
10.2%
5,218,752
SC 13G/A
Feb 09, 2023
vanguard group inc
11.71%
5,956,960
SC 13G/A
Jan 31, 2023
fmr llc
-
0
SC 13G/A
Jan 24, 2023
blackrock inc.
9.8%
4,981,145
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G
Feb 09, 2022
vanguard group inc
11.63%
5,869,125
SC 13G/A
Jan 28, 2022
blackrock inc.
10.1%
5,080,026
SC 13G/A
Feb 10, 2021
vanguard group inc
10.11%
5,027,904
SC 13G/A
Jan 27, 2021
blackrock inc.
10.8%
5,369,613
SC 13G/A
Jul 10, 2020
blackrock inc.
10.8%
5,341,383
SC 13G/A

Recent SEC filings of Charles River Laboratories International

View All Filings
Date Filed Form Type Document
Aug 29, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading
Aug 10, 2023
144
Notice of Insider Sale Intent
Aug 10, 2023
144
Notice of Insider Sale Intent
Aug 10, 2023
144
Notice of Insider Sale Intent
Aug 09, 2023
8-K
Current Report
Aug 09, 2023
10-Q
Quarterly Report

CRL Fair Value

Loading...

Peers (Alternatives to Charles River Laboratories International)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.6B
14.7B
-4.17% 2.88%
34.32
2.56
3.86% -5.52%
32.2B
7.0B
-5.38% -12.23%
28.38
4.6
5.03% -14.68%
21.9B
4.5B
-17.36% -28.94%
-5.22
4.9
-4.92% -21931.58%
10.2B
4.2B
3.84% 7.44%
20.99
2.43
13.29% 9.18%
MID-CAP
7.8B
1.7B
3.55% 63.62%
28.97
4.65
30.05% 28.37%
4.4B
5.4B
0.56% -14.23%
62.28
0.82
0.01% -74.39%
2.9B
256.2M
-5.82% -20.18%
-15.97
11.29
2.51% -17.66%
1.6B
551.6M
-11.36% 31.23%
-13.84
2.88
12.73% 21.90%
SMALL-CAP
589.3M
-
-11.38% -21.30%
-11.41
6.7K
- -13.75%
357.7M
22.1M
-13.04% -47.76%
16.15
16.18
43.14% 124.16%
170.9M
66.2M
-71.28% -88.95%
-0.25
2.73
20.37% -7.56%
118.7M
99.2M
-1.73% -74.89%
-2.09
1.2
-26.56% -199.52%
64.0M
67.1M
-25.42% -59.63%
-0.58
0.95
-12.13% -17.68%

Charles River Laboratories International News

Nasdaq
Surging Bond Yields Hammer Stocks.
Nasdaq,
2 hours ago
Investing.com UK
Nasdaq
S&P 500 Movers: CRL, FDX.
Nasdaq,
9 hours ago
Best Stocks

Returns for CRL

Cumulative Returns on CRL

16.3%


10-Year Cumulative Returns

14.3%


7-Year Cumulative Returns

10.2%


5-Year Cumulative Returns

-1.7%


3-Year Cumulative Returns

Risks for CRL

What is the probability of a big loss on CRL?

56.1%


Probability that Charles River Laboratories International stock will be more than 20% underwater in next one year

42.7%


Probability that Charles River Laboratories International stock will be more than 30% underwater in next one year.

36.5%


Probability that Charles River Laboratories International stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Charles River Laboratories International was unfortunately bought at previous high price.

Drawdowns

Financials for Charles River Laboratories International

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.1%4,1784,0923,9763,7813,6883,6303,5403,4263,2733,0412,9242,8242,7492,7242,6212,5322,4492,3772,2662,1432,022
  S&GA Expenses9.9%758690665610574614620619599555529516517525518495478463444431410
EBITDA-100.0%-1,013986-809814820--787768608587580563515518----
EBITDA Margin-100.0%-0.25*0.25*-0.22*0.22*0.23*--0.26*0.26*0.22*0.21*0.21*0.21*0.20*0.21*----
Interest Expenses37.2%11684.0059.0036.0041.0054.0074.0096.0098.0010186.0078.0064.0066.0061.0053.0065.0063.0064.0055.0045.00
Earnings Before Taxes---623---481---447---304274274285282276275
EBT Margin-100.0%-0.15*0.16*-0.13*0.13*0.14*--0.15*0.15*0.11*0.11*0.11*0.12*0.11*0.11*----
Net Income-2.5%484496486436443422391397396375364301271248252231219229226137129
Net Income Margin-100.0%-0.12*0.12*0.12*0.12*0.12*0.11*0.12*0.12*0.12*0.12*0.11*0.10*0.09*0.10*------
Free Cashflow-100.0%-626620614656693761670672648547589567535481------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets0.9%7,7727,6997,6037,3837,5297,0757,0247,0586,7205,8095,4915,2135,2415,2024,6934,5834,6253,9273,8563,7973,866
  Current Assets3.9%1,5051,4481,4391,4151,3931,3331,2741,3791,2681,4231,2011,1401,2351,2081,0219721,010866898838890
    Cash Equivalents-0.6%200202234194207242246213223465228243402372240165201126197139192
  Inventory8.6%285263256262257221199182194194186181168163161156135130128126124
  Net PPE-----------1,124--1,0331,0441,0081,006907909897896
  Goodwill0.5%2,9172,9022,8502,7762,8602162,7122,73624061272.001,7781,7361,7322101,5221,5271,2461,247--
Liabilities-1.5%4,4724,5434,5794,7114,8364,4044,4324,5944,3663,5933,3473,2883,4603,5223,0263,0183,1472,5052,5182,5232,664
  Current Liabilities2.7%1,0089811,0921,0141,0489941,033984930803840787728691710682636530558540518
  Long Term Debt-2.4%2,6782,7442,7082,9372,9972,6762,6642,8932,7272,2021,9301,9682,2072,3271,8501,8832,0401,5411,6371,6531,796
Shareholder's Equity4.4%3,2523,1142,9762,6272,6532,6152,5392,4322,3232,1882,1181,9011,7571,6561,6381,5361,4581,4011,3201,2571,185
  Retained Earnings6.3%1,6331,5361,4331,2801,1831,07498187977568762550139933128021414197.0042.00460400
  Additional Paid-In Capital1.1%1,8501,8301,8051,7811,7611,7451,7181,7201,6911,6601,6281,6141,5901,5631,5321,5151,4981,4811,4482,6252,609
Shares Outstanding0.2%51.0051.0051.0051.0051.0051.0050.0050.0050.0050.0050.0050.0050.0049.0049.0049.0049.0048.0048.0048.0048.00
Minority Interest10.7%6.005.005.006.005.005.004.005.005.004.004.005.004.004.003.004.003.003.002.004.003.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-0.2%625626620614656693761670672648547589567535481440402396441425368
  Share Based Compensation1.8%74.0072.0074.0071.0071.0073.0071.0068.0063.0059.0056.0055.0052.0055.0057.0055.0053.0050.0047.0047.0047.00
Cashflow From Investing56.8%-293-678-607-643-905-1,397-1,437-1,535-1,251-325-601-583-574-1,074-681-681-653-951-955-916-937
Cashflow From Financing-8853.6%-346-3.87-42.40-12.41218465673832385-23747.0067.00203780232272258504558504651
  Buy Backs2.1%24.0024.0039.0039.0039.0039.0041.0041.0040.0036.0024.0024.0024.0024.0018.0018.0018.0018.0014.0014.0050.00

CRL Income Statement

2023-07-01
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jul. 01, 2023
Jun. 25, 2022
Jul. 01, 2023
Jun. 25, 2022
Total revenue$ 1,059,937$ 973,131$ 2,089,310$ 1,887,060
Costs and expenses:    
Selling, general and administrative199,758131,711374,604281,744
Amortization of intangible assets34,27437,60469,19075,611
Operating income164,945187,411332,837336,189
Other income (expense):    
Interest income1,4261882,232315
Interest expense(35,044)(3,703)(69,424)(13,137)
Other expense, net(2,663)(39,783)(5,940)(68,408)
Income before income taxes128,664144,113259,705254,959
Provision for income taxes29,22133,44956,30849,069
Net income99,443110,664203,397205,890
Less: Net income attributable to noncontrolling interests2,4231,3433,2463,547
Net income attributable to common shareholders$ 97,020$ 109,321$ 200,151$ 202,343
Earnings per common share    
Basic (in dollars per share)$ 1.89$ 2.15$ 3.91$ 3.99
Diluted (in dollars per share)$ 1.89$ 2.13$ 3.90$ 3.94
Weighted-average number of common shares outstanding:    
Basic (in shares)51,21650,82351,15750,732
Diluted (in shares)51,46751,28351,38251,293
Service    
Total revenue$ 874,891$ 782,827$ 1,732,257$ 1,503,312
Costs and expenses:    
Cost of services provided and products sold (excluding amortization of intangible assets)578,099522,6231,143,5761,009,487
Product    
Total revenue185,046190,304357,053383,748
Costs and expenses:    
Cost of services provided and products sold (excluding amortization of intangible assets)$ 82,861$ 93,782$ 169,103$ 184,029

CRL Balance Sheet

2023-07-01
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Jul. 01, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 200,445$ 233,912
Trade receivables and contract assets, net of allowances for credit losses of $18,040 and $11,278, respectively800,646752,390
Inventories285,280255,809
Prepaid assets105,02089,341
Other current assets113,389107,580
Total current assets1,504,7801,439,032
Property, plant and equipment, net1,529,6401,465,655
Venture capital and strategic equity investments300,281311,602
Operating lease right-of-use assets, net397,192391,762
Goodwill2,916,5932,849,903
Intangible assets, net929,890955,275
Deferred tax assets38,54041,262
Other assets155,465148,279
Total assets7,772,3817,602,770
Current liabilities:  
Accounts payable140,204205,915
Accrued compensation190,802197,078
Deferred revenue257,396264,259
Accrued liabilities220,704219,758
Other current liabilities198,517204,575
Total current liabilities1,007,6231,091,585
Long-term debt, net and finance leases2,678,4722,707,531
Operating lease right-of-use liabilities401,628389,745
Deferred tax liabilities207,404215,582
Other long-term liabilities177,252174,822
Total liabilities4,472,3794,579,265
Commitments and contingencies (Notes 2, 8, 10, and 12)
Redeemable noncontrolling interest42,44742,427
Equity:  
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding00
Common stock, $0.01 par value; 120,000 shares authorized; 51,370 shares issued and 51,266 shares outstanding as of July 1, 2023, and 50,944 shares issued and outstanding as of December 31, 2022513509
Additional paid-in capital1,850,3851,804,940
Retained earnings1,633,0521,432,901
Treasury stock, at cost, 104 and zero shares, as of July 1, 2023 and December 31, 2022, respectively(23,978)0
Accumulated other comprehensive loss(208,269)(262,057)
Total equity attributable to common shareholders3,251,7032,976,293
Noncontrolling interests (nonredeemable)5,8524,785
Total equity3,257,5552,981,078
Total liabilities, redeemable noncontrolling interests and equity$ 7,772,381$ 7,602,770
James C. Foster
20000
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.